As you might know, Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) last week released its latest quarterly, and things did not turn out so great for shareholders. It was a pretty negative result overall, with revenues of US$73m missing analyst predictions by 8.2%. Additionally, the business reported a statutory loss of US$0.55 per share, larger than the analysts had forecast prior to the result. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Following the latest results, Syndax Pharmaceuticals' eleven analysts are now forecasting revenues of US$317.9m in 2026. This would be a major 26% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 19% from last year to US$2.00. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$344.8m and losses of US$1.68 per share in 2026. So it's pretty clear the analysts have mixed opinions on Syndax Pharmaceuticals after this update; revenues were downgraded and per-share losses expected to increase.

There was no major change to the consensus price target of US$38.27, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Syndax Pharmaceuticals analyst has a price target of US$57.00 per share, while the most pessimistic values it at US$26.00. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that Syndax Pharmaceuticals' rate of growth is expected to accelerate meaningfully, with the forecast 59% annualised revenue growth to the end of 2026 noticeably faster than its historical growth of 28% p.a. over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 23% annually. Factoring in the forecast acceleration in revenue, it's pretty clear that Syndax Pharmaceuticals is expected to grow much faster than its industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Syndax Pharmaceuticals. They also downgraded Syndax Pharmaceuticals' revenue estimates, but industry data suggests that it is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Syndax Pharmaceuticals going out to 2028, and you can see them free on our platform here..

You can also view our analysis of Syndax Pharmaceuticals' balance sheet, and whether we think Syndax Pharmaceuticals is carrying too much debt, for free on our platform here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.